Health and Healthcare
Is Immunogen Done After This Ovarian Cancer Study?
Published:
Last Updated:
ImmunoGen Inc. (NASDAQ: IMGN) shares were halved on Friday after the firm reported late-stage results from its ovarian cancer study.
Specifically, the results from its Phase 3 Forward 1 trial evaluating the safety and efficacy of mirvetuximab soravtansine compared to chemotherapy in patients with folate receptor alpha (FRα)-positive, platinum-resistant ovarian cancer.
Ultimately, the trial did not meet its primary endpoint of progression-free surviva in either the entire study population or in the prespecified subset of patients with high FRα expression. The primary endpoint was assessed using the Hochberg procedure in the entire study population and in the subset of patients with high FRα expression.
The firm did not have much to say about what it has planned in the future except that it intends to present additional results from Forward 1 at an upcoming medical meeting.
Dr. Kathleen Moore, associate director of Clinical Research at the Stephenson Cancer Center at the University of Oklahoma, commented:
Even though FORWARD I did not meet its primary endpoint, I continue to be impressed with the efficacy and tolerability of mirvetuximab soravtansine in ovarian cancer patients, especially in the subset with high FRα expression. I look forward to continuing to work with ImmunoGen to analyze the Phase 3 data and determine the most appropriate path to bringing mirvetuximab soravtansine to those patients who benefit most from it.
Shares of ImmunoGen were last seen down 49% at $2.41, in a 52-week range of $2.27 to $13.41.
24/7 Wall St.Take Charge of Your Retirement In Just A Few Minutes (Sponsor)
Retirement planning doesn’t have to feel overwhelming. The key is finding expert guidance—and SmartAsset’s made it easier than ever for you to connect with a vetted financial advisor.
Here’s how it works:
- Answer a Few Simple Questions. Tell us a bit about your goals and preferences—it only takes a few minutes!
- Get Matched with Vetted Advisors Our smart tool matches you with up to three pre-screened, vetted advisors who serve your area and are held to a fiduciary standard to act in your best interests. Click here to begin
- Choose Your Fit Review their profiles, schedule an introductory call (or meet in person), and select the advisor who feel is right for you.
Why wait? Start building the retirement you’ve always dreamed of. Click here to get started today!
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.